Elanco Animal Health (NYSE:ELAN) Price Target Raised to $30.00 at Leerink Partners

Elanco Animal Health (NYSE:ELAN) had its target price boosted by Leerink Partners from $26.00 to $30.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Leerink Partners’ target price suggests a potential upside of 16.00% from the stock’s current price.

Several other equities analysts have also commented on the company. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research report on Wednesday, November 19th. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 29th. Finally, Barclays assumed coverage on shares of Elanco Animal Health in a report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.22.

Elanco Animal Health Price Performance

Shares of ELAN traded up $1.11 during mid-day trading on Tuesday, reaching $25.86. 6,036,845 shares of the stock traded hands, compared to its average volume of 4,624,193. The company has a market cap of $12.85 billion, a price-to-earnings ratio of 430.66, a price-to-earnings-growth ratio of 3.73 and a beta of 1.87. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average price of $23.90 and a 200 day moving average price of $21.55. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $26.87.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.02. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. Elanco Animal Health’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Activity at Elanco Animal Health

In other news, insider Rajeev A. Modi acquired 4,500 shares of the stock in a transaction on Thursday, December 11th. The stock was acquired at an average price of $21.33 per share, with a total value of $95,985.00. Following the completion of the transaction, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. This represents a 3.79% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 22,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average cost of $21.75 per share, for a total transaction of $478,500.00. Following the purchase, the chief executive officer directly owned 167,000 shares of the company’s stock, valued at $3,632,250. This represents a 15.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 43,450 shares of company stock valued at $937,883 in the last three months. Corporate insiders own 0.89% of the company’s stock.

Institutional Trading of Elanco Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Kera Capital Partners Inc. lifted its position in Elanco Animal Health by 79.0% in the 4th quarter. Kera Capital Partners Inc. now owns 21,735 shares of the company’s stock valued at $523,000 after acquiring an additional 9,595 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its stake in shares of Elanco Animal Health by 11.8% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after purchasing an additional 3,717,404 shares during the last quarter. Compound Planning Inc. lifted its holdings in shares of Elanco Animal Health by 29.7% during the fourth quarter. Compound Planning Inc. now owns 21,312 shares of the company’s stock valued at $482,000 after purchasing an additional 4,876 shares in the last quarter. Invesco Ltd. boosted its position in shares of Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after buying an additional 3,690,735 shares during the last quarter. Finally, Corient Private Wealth LLC increased its holdings in Elanco Animal Health by 122.3% in the 4th quarter. Corient Private Wealth LLC now owns 165,381 shares of the company’s stock worth $3,743,000 after buying an additional 90,993 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

More Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q4 results beat expectations — adjusted EPS $0.13 vs. consensus $0.11 and revenue $1.144B (+12% y/y), driven by innovation and commercial momentum; adjusted EBITDA of $189M. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Management raised FY2026 targets for innovation revenue and issued revenue/adjusted EBITDA guidance (Revenue $4.95–5.02B; Adj. EBITDA $955–985M; Adj. EPS $1.00–1.06) and a lower year‑end net leverage target (3.1x–3.3x vs. 3.6x now) — supports confidence in margin and cash recovery. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Product progress: company delivered its “Big 6” blockbusters with Befrena approval in Q4 and innovation revenue reached $892M in 2025; management raised the 2026 innovation target to $1.15B — supports medium-term growth story. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Q1 FY2026 guidance set at $0.33–0.36 EPS and ~$1.3B revenue — roughly in line with street expectations (range contains consensus), so minimal surprise near-term. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst tone: some upward price-target moves (e.g., BofA raised PT to $28) reflecting the beat/guidance but ratings remain mixed; watch sell‑side revisions. Where is Elanco Animal Health Incorporated (ELAN) Headed According to the Street?
• Negative Sentiment: GAAP results still showed a reported net loss (Q4 and FY), and leverage remains elevated (net leverage ~3.6x at year‑end) — execution on deleveraging and cash conversion is a key risk. Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Business/portfolio risk: the company’s dermatology push is highlighted as a potential make-or-break investment area — success/failures here could swing sentiment materially. Elanco Animal Health earnings on deck as dermatology bet looms

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.